Lightcast Opens Innovation Center in United States to Support Global Expansion of Luminary Early Access Program
13 Mayo 2024 - 7:03AM
Business Wire
Company to showcase droplet-based platform and targeted drug and
therapeutics applications at 20th annual PEGS Boston Summit
Lightcast Discovery Ltd., a life science tools company
developing a novel single-cell functional analysis platform, today
announced the opening of its new Innovation Center in the United
States to accelerate the global expansion of its Luminary early
access program (EAP). Located within the LabCentral community in
Cambridge, Mass., the new office and laboratory facility will
augment the company’s Cambridge, UK, headquarters and provide
regional support to its growing list of collaborators across North
America.
Lightcast is advancing single-cell functional analysis with a
droplet-based platform that can load, select, process, analyze, and
recover tens of thousands to hundreds of thousands of individual
cells at the same time. This novel technology enables the
manipulation of addressable picoliter droplets with light in a
massively parallel manner, enabling sequential assays querying
individual cell function and cell-cell interactions. Lightcast’s
platform provides the flexibility to analyze a wide range of cell
types and assays, as well as the precision to meticulously control
and monitor the number, occupancy, location, and movement of each
droplet. The approach will streamline workflows for drug discovery
and development, and promote translational and basic research
advancements.
“In the second half of 2023, we launched the Luminary early
access program to engage with leading experts in translational
research and drug development, enabling us to collaboratively
refine and enhance our respective technologies and workflows,” said
Paul Steinberg, CCO at Lightcast. “We now have a growing number of
European and North American laboratories participating, and today I
am delighted to announce the expansion of the Luminary EAP to
ensure we prioritize the development of applications that promise
the highest impact on scientific advancement and therapeutic
development.”
Lightcast's Luminary program enables royalty-free,
pre-commercial technology access and is designed to showcase the
full utility of the technology in important drug development and
translational research. The Innovation Center will also provide
access to partners across the LabCentral community, many of whom
are focused on the development of cell-based therapies that can be
further accelerated by the Lightcast technology.
With the expansion of the Luminary EAP, Lightcast is seeking
collaborative partners who are interested in being among the first
to evaluate and apply the unprecedented flexibility and scalability
of its droplet-based technology. To set up a platform demonstration
or to learn more about the Luminary EAP, visit
www.lightcast.bio/luminary-program.
Lightcast will be showcasing its novel technology platform and
sharing early access collaborator successes during the PEGS Boston
Summit this week in booth #706. Kathrin Herbst, PhD, Director of
Science and Business Development at Lightcast, will be giving a
presentation about how to accelerate drug development with
flexible, scalable, single-cell functional analysis on Monday, May
13, at 10:00 am ET. For more information on the conference, please
visit www.pegsummit.com.
About Lightcast
Lightcast Discovery aims to unleash new capabilities within the
single-cell analysis field by developing a more accessible,
scalable, and flexible platform for scientists in basic,
translational, and applied research. These capabilities will
empower new biological discoveries and accelerate the development
of novel drugs, therapies, and biologics. Founded in 2019 and based
in Cambridge, UK, Lightcast has invented a technology that uses
rays of light to control picoliter-scale droplets for functional
analysis of individual cells. For more information, visit
www.lightcast.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513024668/en/
Andrew Noble for Lightcast Discovery Ltd. andrew@bioscribe.com
+1 (415) 722-2129